– CANADA, Toronto – Antibe Therapeutics Inc. (TSXV:ATE, OTCQX:ATBPF), a commercial-stage pharmaceutical growth company, is pleased to announce the appointment of Yung Wu to its Board of Directors.
“We’re delighted by the addition of Yung to our Board of Directors. We see many growth opportunities ahead for Antibe and we will benefit from Yung’s unique insights and perspectives as we work to unlock the full potential of the Company,” said Walt Macnee, Antibe’s Chair of the Board. “We look forward to continuing a long-term growth trajectory that maximizes shareholder value.”
Mr. Wu is Managing Director of private equity firm NFQ Ventures and is a seasoned entrepreneur with a track record of successfully building and growing several businesses throughout his career. As a serial founder and CEO, he has personally built 7 companies and produced multiple successful exits to acquirers such as Upsight and Oracle Financial Services. He also serves as a director on the Board of Green Shield, a multi-billion dollar health benefits insurance and financial services company. Mr. Wu will serve as an independent director of Antibe and is also a shareholder.
In addition, Antibe is pleased to announce recruitment of its final patient to its Phase 2 clinical trial examining the efficacy of ATB-346 in patients with osteoarthritis. Antibe anticipates that final results will be available for release by mid-August. The primary endpoints of the Phase 2 study are clinical assessments of pain and inflammation over the course of 10 days of treatment with ATB-346 at 250 mg once daily.
About Yung Wu
Yung is a serial founder and entrepreneur, technology innovator, private equity investor and Corporate Director. He has created, led, financed and directed companies spanning enterprise software, mobile technology, entertainment & media, financial services and oil & gas exploration. Yung has been recognized as one of Canada’s ‘Top 40 under 40’ leaders and for leading one of the “50 Best Managed Private Companies” in the nation. He has a bachelor’s degree in Computer Science, Economics and Mathematics from the University of Toronto, a graduate of the Entrepreneurial Masters Program at the Massachusetts Institute of Technology, a member of MENSA, the Young Presidents Organization and the Institute of Corporate Directors.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.